[
  {
    "ts": null,
    "headline": "SDOW: Benefits And Risks Of The Leveraged Bear Dow Jones ETF",
    "summary": "The ProShares UltraPro Short Dow30 ETF offers -3X daily exposure to the Dow Jones Industrial Average, primarily serving short-term traders. Click here to learn more.",
    "url": "https://finnhub.io/api/news?id=eb8a1440101254b79276269c64e31af52876fc07574160bd48fd0e1f4fddb21c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770834130,
      "headline": "SDOW: Benefits And Risks Of The Leveraged Bear Dow Jones ETF",
      "id": 139050295,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/620925375/image_620925375.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "The ProShares UltraPro Short Dow30 ETF offers -3X daily exposure to the Dow Jones Industrial Average, primarily serving short-term traders. Click here to learn more.",
      "url": "https://finnhub.io/api/news?id=eb8a1440101254b79276269c64e31af52876fc07574160bd48fd0e1f4fddb21c"
    }
  },
  {
    "ts": null,
    "headline": "Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica",
    "summary": "High-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers. The market is bifurcating, with innovation focused on severe phenotypes and smart delivery, while policy shifts mandate affordability for mass-market generic access.Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The global asthma drugs market size was valued at USD 26.52 billion in 2025 and is projected to hit the market valuation of USD 41.18 billion by 2035 at a CAGR",
    "url": "https://finnhub.io/api/news?id=9eb93c2a9303607e4efdb371e91b4f15d6786971393a66b62e863bfeed3f0723",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828540,
      "headline": "Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica",
      "id": 139045990,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "High-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers. The market is bifurcating, with innovation focused on severe phenotypes and smart delivery, while policy shifts mandate affordability for mass-market generic access.Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The global asthma drugs market size was valued at USD 26.52 billion in 2025 and is projected to hit the market valuation of USD 41.18 billion by 2035 at a CAGR",
      "url": "https://finnhub.io/api/news?id=9eb93c2a9303607e4efdb371e91b4f15d6786971393a66b62e863bfeed3f0723"
    }
  },
  {
    "ts": null,
    "headline": "2 Urgent Sells And 2 No Brainer Dividend Buys",
    "summary": "It is in our best approach to sell high and buy low. Here's how to approach it systematically today with 2 SELLS and 2 BUYS. Read the full article here.",
    "url": "https://finnhub.io/api/news?id=710180ef6607cf998857b15aaa54b1cbd366e4e984f58dca1a1a55930c6f0ac2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770826010,
      "headline": "2 Urgent Sells And 2 No Brainer Dividend Buys",
      "id": 139048960,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2396885/image_2396885.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "It is in our best approach to sell high and buy low. Here's how to approach it systematically today with 2 SELLS and 2 BUYS. Read the full article here.",
      "url": "https://finnhub.io/api/news?id=710180ef6607cf998857b15aaa54b1cbd366e4e984f58dca1a1a55930c6f0ac2"
    }
  },
  {
    "ts": null,
    "headline": "Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose",
    "summary": "Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.",
    "url": "https://finnhub.io/api/news?id=ba95585f56ede4512033a78e2ba72d47cc1d49832cef4c75a1e5abf4b36c10bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770821746,
      "headline": "Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose",
      "id": 139045137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.",
      "url": "https://finnhub.io/api/news?id=ba95585f56ede4512033a78e2ba72d47cc1d49832cef4c75a1e5abf4b36c10bd"
    }
  },
  {
    "ts": null,
    "headline": "Review & Preview: Consumers Show Strain",
    "summary": "While the Dow notched its seventh record of the year, the broader S&P 500 slipped. Plus, retail sales weaken.",
    "url": "https://finnhub.io/api/news?id=13af846bd91057c04cabc17f7395d7f70832384efb210c6a246c059150c5b978",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770771300,
      "headline": "Review & Preview: Consumers Show Strain",
      "id": 139038314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While the Dow notched its seventh record of the year, the broader S&P 500 slipped. Plus, retail sales weaken.",
      "url": "https://finnhub.io/api/news?id=13af846bd91057c04cabc17f7395d7f70832384efb210c6a246c059150c5b978"
    }
  }
]